Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CERS
stocks logo

CERS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
56.64M
+11.47%
-0.025
+25%
51.63M
+19.41%
-0.005
-50%
59.66M
+13.76%
-0.030
-25%
Estimates Revision
The market is revising Downward the revenue expectations for Cerus Corporation (CERS) for FY2025, with the revenue forecasts being adjusted by -3.04% over the past three months. During the same period, the stock price has changed by 57.89%.
Revenue Estimates for FY2025
Revise Downward
down Image
-3.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-23.81%
In Past 3 Month
Stock Price
Go Up
up Image
+57.89%
In Past 3 Month
Wall Street analysts forecast CERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERS is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERS is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.100
sliders
Low
4.00
Averages
4.50
High
5.00
Current: 2.100
sliders
Low
4.00
Averages
4.50
High
5.00
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$4
2025-02-21
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$4
2025-02-21
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cerus Corp (CERS.O) is -60.00, compared to its 5-year average forward P/E of -19.49. For a more detailed relative valuation and DCF analysis to assess Cerus Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-19.49
Current PE
-60.00
Overvalued PE
-11.91
Undervalued PE
-27.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
56.79
Undervalued EV/EBITDA
-69.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.84
Current PS
0.00
Overvalued PS
6.61
Undervalued PS
1.06
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CERS News & Events

Events Timeline

(ET)
2025-11-06
16:11:11
Cerus Announces Q3 EPS of 0c, Falling Short of Two Estimates (3c)
select
2025-08-25 (ET)
2025-08-25
09:08:49
Cerus reveals new guidance issued by German advisory committee
select
2025-08-05 (ET)
2025-08-05
16:14:01
Cerus reports Q2 EPS (3c), consensus (2c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
10-21Newsfilter
Cerus Corporation Unveils Abstracts and Hosts Industry Workshop on IFC at the 2025 AABB Annual Meeting

  • Cerus Corporation Workshop Announcement: Cerus Corporation will host a workshop on the benefits of INTERCEPT Fibrinogen Complex at the 2025 AABB Annual Meeting in San Diego, emphasizing their commitment to innovations in transfusion medicine.

  • Abstract Presentations: Eighteen Cerus-related abstracts will be presented at the AABB meeting, showcasing the impact of their technologies on blood safety and availability.

  • Workshop Details: The workshop, scheduled for October 27, 2025, will feature speakers from the University of California, San Diego, and OneBlood, focusing on blood center perspectives regarding INTERCEPT Fibrinogen Complex.

  • Company Overview: Cerus Corporation is dedicated to enhancing blood safety through its INTERCEPT Blood System, which is globally available and FDA-approved for pathogen reduction in blood components.

[object Object]
Preview
4.0
09-21NASDAQ.COM
Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - September 20, 2025

  • Validea's Growth/Value Investor Model: The model, based on James P. O'Shaughnessy's strategy, evaluates large-cap value and growth stocks, with Cerus Corp (CERS) receiving a rating increase from 75% to 100% due to strong fundamentals and valuation.

  • Cerus Corporation Overview: Cerus is a biomedical company focused on the INTERCEPT Blood System, which enhances blood safety by reducing pathogens in blood components for transfusion, including platelets and plasma.

[object Object]
Preview
8.5
07-21Newsfilter
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury

  • Funding Announcement: Cerus Corporation has received an additional $7.2 million from the U.S. Department of Defense to support a randomized study, CRYO-FIRST, evaluating the use of INTERCEPT Fibrinogen Complex (IFC) for treating trauma-associated hemorrhagic shock patients.

  • Study Objectives: The CRYO-FIRST study aims to compare IFC with conventional cryoprecipitated antihemophilic factor in trauma patients, focusing on increasing plasma fibrinogen levels and assessing safety, with initial patient enrollment expected in 2026.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cerus Corp (CERS) stock price today?

The current price of CERS is 2.1 USD — it has increased 5.53 % in the last trading day.

arrow icon

What is Cerus Corp (CERS)'s business?

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

arrow icon

What is the price predicton of CERS Stock?

Wall Street analysts forecast CERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERS is 4.50 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cerus Corp (CERS)'s revenue for the last quarter?

Cerus Corp revenue for the last quarter amounts to 60.24M USD, increased 18.91 % YoY.

arrow icon

What is Cerus Corp (CERS)'s earnings per share (EPS) for the last quarter?

Cerus Corp. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cerus Corp (CERS)'s fundamentals?

The market is revising Downward the revenue expectations for Cerus Corporation (CERS) for FY2025, with the revenue forecasts being adjusted by -3.04% over the past three months. During the same period, the stock price has changed by 57.89%.
arrow icon

How many employees does Cerus Corp (CERS). have?

Cerus Corp (CERS) has 281 emplpoyees as of December 05 2025.

arrow icon

What is Cerus Corp (CERS) market cap?

Today CERS has the market capitalization of 381.29M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free